Clincosm LogoSign in Get a demo

Portal Blood Flushes in the Peri-Reperfusion Stage of Liver Transplantation

Sponsor
Medical University of South Carolina (Other)
Overall Status
Completed
CT.gov ID
NCT03563404
Collaborator
(none)
20
Enrollment
1
Location
12
Duration (Months)
1.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

By showing that increased levels of acidotic metabolites and electrolytes in the systemic blood of patients who do not receive portal blood flush prior to reperfusion compared to patients who do receive portal blood flush, and that these increased levels correlate with cardiac depression as seen on TEE, the investigators hope to find a superior technique for liver reperfusion.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    20 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Are Portal Blood Flushes Useful in Maintaining Hemodynamic Stability in the Peri-Reperfusion Stage of Orthotopic Liver Transplantation
    Study Start Date :
    Jun 29, 2015
    Actual Primary Completion Date :
    Jun 29, 2016
    Actual Study Completion Date :
    Jun 29, 2016

    Arms and Interventions

    Arm Intervention/Treatment
    Portal Blood Flush

    participants that receive the portal blood flush
    No Portal Blood Flush

    participants that don't receive the portal blood flush

    Outcome Measures

    Primary Outcome Measures

    1. Hemodynamic Stability [5 days]

      The primary objective of this study is to determine whether or not a portal blood flush is useful for maintaining hemodynamic stability in the peri-reperfusion stage of Orthotopic Liver Transplantation as evidence by TEE.

    Secondary Outcome Measures

    1. correlation between the cardiac dysfunction and the degree of hyperkalemia seen after reperfusion. [5 days]

      The secondary objective is to determine if there is a correlation between cardiac dysfunction as measured by a qualitative analysis of TEE and the degree of hyperkalemia measured by a post reperfusion blood sample.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Liver Transplantation

    • 18 years old or older

    Exclusion Criteria:
    • None

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Medical University of South Carolina Charleston South Carolina United States 29425

    Sponsors and Collaborators

    • Medical University of South Carolina

    Investigators

    • Principal Investigator: Grayce Davis, MD, Medical University of South Carolina

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Medical University of South Carolina
    ClinicalTrials.gov Identifier:
    NCT03563404
    Other Study ID Numbers:
    • Pro00044952
    First Posted:
    Jun 20, 2018
    Last Update Posted:
    Jul 3, 2018
    Last Verified:
    Jul 1, 2018
    Additional relevant MeSH terms:
    Liver Diseases

    Study Results

    No Results Posted as of Jul 3, 2018